Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M.

J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680.

PMID:
23547081
2.

Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.

Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C.

Jpn J Clin Oncol. 2015 Dec;45(12):1122-30. doi: 10.1093/jjco/hyv141.

PMID:
26518328
3.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
4.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
5.
6.

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, Sugimori K, Furuse J, Shimada K, Ioka T, Nakamori S, Baba H, Komatsu Y, Takeuchi M, Hyodo I, Boku N.

Ann Oncol. 2016 Mar;27(3):502-8. doi: 10.1093/annonc/mdv603.

7.

Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).

Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J.

Jpn J Clin Oncol. 2010 Dec;40(12):1189-91. doi: 10.1093/jjco/hyq110.

PMID:
20630899
8.

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.

Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K.

Oncology. 2005;69(5):421-7.

PMID:
16319514
9.

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS.

Jpn J Clin Oncol. 2009 Jan;39(1):49-53. doi: 10.1093/jjco/hyn126.

PMID:
19060295
10.

A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K.

Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9. doi: 10.1007/s00280-013-2090-4.

PMID:
23355041
11.

Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.

Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):845-52. doi: 10.1007/s00280-013-2265-z.

PMID:
23978987
12.

Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.

Kawashima H, Itoh A, Ohno E, Nakamura M, Miyahara R, Ohmiya N, Hara K, Kanamori A, Itoh T, Taki T, Hirai T, Hashimoto S, Takeda K, Goto H, Hirooka Y.

Cancer Chemother Pharmacol. 2011 Sep;68(3):677-83. doi: 10.1007/s00280-010-1531-6.

PMID:
21132496
13.

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.

Cancer Chemother Pharmacol. 2010 Feb;65(3):527-36. doi: 10.1007/s00280-009-1059-9.

PMID:
19578850
14.

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.

Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH.

Cancer Chemother Pharmacol. 2009 Sep;64(4):707-13. doi: 10.1007/s00280-008-0918-0.

PMID:
19151975
15.

Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.

Togawa A, Yoshitomi H, Ito H, Kimura F, Shimizu H, Ohtsuka M, Yoshidome H, Kato A, Sawada S, Miyazaki M.

Int J Clin Oncol. 2007 Aug;12(4):268-73.

PMID:
17701005
16.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
17.

Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).

Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J.

Cancer Sci. 2013 Sep;104(9):1211-6. doi: 10.1111/cas.12218.

18.

A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.

Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M.

Oncology. 2009;77(5):300-3. doi: 10.1159/000259616.

PMID:
19923869
19.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M.

Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4.

PMID:
18282805
20.

A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.

Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, Mitsunaga S, Shimizu S.

Cancer Chemother Pharmacol. 2010 Aug;66(3):527-34. doi: 10.1007/s00280-009-1193-4.

PMID:
19967537

Supplemental Content

Support Center